Global EditionASIA 中文雙語Fran?ais
    China
    Home / China / Latest

    Nation's rapid response led to vaccine 'miracle'

    By WANG XIAODONG | China Daily Global | Updated: 2021-02-22 09:58
    Share
    Share - WeChat
    A cargo container of COVID-19 vaccine is unloaded at the airport in Mexico City, Mexico, on Saturday as Mexico received its first shipment of vaccines made by Chinese company Sinovac. XIN YUEWEI/XINHUA

    When Wu Guizhen and her colleagues at the Chinese Center for Disease Control and Prevention in Beijing received their first sample of an unknown virus on Jan 2,2020, they immediately rushed to identify it.

    The sample had been collected from a pneumonia patient in Wuhan, Hubei province.

    "It's similar to when you cannot see the enemy during a war if you cannot get a clear picture of a virus when fighting an infectious disease," said Wu, chief biosafety expert at the China CDC.

    In the initial days of the COVID-19 outbreak, when the disease was referred to as "pneumonia caused by unknown causes", Wu and other virologists at China CDC's National Institute for Viral Disease Control and Prevention had never been busier. The virologists worked around the clock to analyze the sample using the latest technology. Some of them slept at their workplace for days, she said.

    In less than a week, on Jan 7, China CDC researchers had successfully isolated a new coronavirus from the sample.

    The next day, a team of experts from the National Health Commission gave initial confirmation that the novel coronavirus was the cause of the epidemic in Wuhan. The following day, China shared the information with the World Health Organization.

    "Preliminary identification of a novel virus in a short period of time is a notable achievement," the WHO said in a statement on Jan 9. "The preliminary determination of a novel virus will assist authorities in other countries to conduct disease detection and response."

    Meanwhile, China CDC began releasing data on the virus, and the genome sequence of the virus was made available for global access through the Global Initiative on Sharing All Influenza Data on Jan 10, Wu said.

    In the following days, two other Chinese institutes-the Chinese Academy of Sciences and the Chinese Academy of Medical Sciences-also released data on the virus' genome sequence to the platform for global sharing, she said.

    The timely release of information on the novel coronavirus greatly facilitated research and development of COVID-19 vaccines across the world, which has made "the miracle" of market approval of vaccines possible within one year of the identification of a disease, Wu said.

    "Following the release of the genome sequence, all countries were able to produce testing kits for the virus, or research and develop vaccines," Wu said. "It also laid the foundation for research in tracing the virus' origin, monitoring its mutation trends and figuring out how the virus causes sickness."

    For example, BNT162b2, which was one of the earliest COVID-19 vaccines available for use, was developed soon after the release of the information. The RNA vaccine was developed by pharmaceutical giant Pfizer and German company BioNTech, and approved for emergency use in the United Kingdom in December.

    "The development of BNT162b2 was initiated on Jan 10, 2020, when the SARS-CoV-2 genetic sequence was released by the Chinese Center for Disease Control and Prevention and disseminated globally by the GISAID initiative," said a paper published in the New England Journal of Medicine in December.

    Wu said "information-sharing is a major contribution China has made to the global fight against the COVID-19 pandemic". She added that such sharing, including origin-tracing, with WHO and the international community, began at the start of the epidemic.

    Wu Zunyou, chief epidemiologist at China CDC, said in an earlier interview with China Daily that China's quick identification of the pathogen and development of testing kits played an important role in the rapid containment of the epidemic in China.

    The global sharing of the genome sequence also greatly contributed to the worldwide fight against the pandemic. "We did not apply for patents for the research and instead made it free for the public good of all," Wu said.

    Top
    BACK TO THE TOP
    English
    Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
    License for publishing multimedia online 0108263

    Registration Number: 130349
    FOLLOW US
     
    亚洲AV无码专区亚洲AV伊甸园| 精品久久久久久无码中文字幕一区| 色欲A∨无码蜜臀AV免费播| 中文字幕AV一区中文字幕天堂| 无码国产精品一区二区免费16| 中文www新版资源在线| 无码毛片一区二区三区中文字幕 | 久久亚洲2019中文字幕| 亚洲人成无码网WWW| 国产在线无码不卡影视影院| 乱人伦中文视频高清视频| 中文字幕色AV一区二区三区| 91无码人妻精品一区二区三区L| 久久无码专区国产精品发布| 人妻无码中文久久久久专区| 久久无码精品一区二区三区| 午夜福利无码不卡在线观看| 中文字幕1级在线| 7国产欧美日韩综合天堂中文久久久久| 成人午夜精品无码区久久| 狠狠躁天天躁无码中文字幕图| 亚洲高清无码综合性爱视频| 亚洲精品无码不卡| 亚洲Av无码精品色午夜 | 亚洲情XO亚洲色XO无码| 合区精品久久久中文字幕一区 | 亚洲乱码中文字幕综合234| 婷婷综合久久中文字幕| 人妻中文字系列无码专区| 欧美日韩久久中文字幕| 久久无码AV中文出轨人妻| 亚洲精品无码专区2| 超清中文乱码字幕在线观看| 亚洲精品欧美精品中文字幕| 国产成人一区二区三中文| 中文字幕人妻无码专区| 91中文字幕yellow字幕网| 最近中文字幕高清字幕在线视频| 久久有码中文字幕| 亚洲成AV人片在线观看无码 | 久久精品无码午夜福利理论片|